News

09.03.20

Press Release

Achieve Life Sciences to Present at Upcoming Investor Conferences

SEATTLE, Wash. and VANCOUVER, British Columbia, September 3, 2020 – – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it will present at two upcoming investor conferences. H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16th…

/Read More

08.06.20

Press Release

Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program

SEATTLE, Wash and VANCOUVER, British Columbia, August 6, 2020 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter 2020 financial results and provided an update on the cytisinicline clinical development program. Recent Highlights Announced…

/Read More

08.04.20

Press Release

Achieve Life Sciences Announces Pricing of $6.5 Million Public Offering

SEATTLE, Wash. and VANCOUVER, British Columbia, August 4, 2020 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the pricing of an underwritten public offering of 476,187 shares of its common stock at a price to…

/Read More

08.03.20

Press Release

Achieve Life Sciences Announces Proposed Public Offering

SEATTLE, Wash. and VANCOUVER, British Columbia, August 3. 2020 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock…

/Read More

07.31.20

Press Release

Achieve Announces Patent Granted in the U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications

SEATTLE, Wash and VANCOUVER, British Columbia, July 31, 2020 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the United States Patent and Trademark Office has granted Achieve a patent (US 2020/0172544 A1) on novel analogs of cytisinicline,…

/Read More